On the one hand, research evidence shows that high expression levels of SIRT7 are associated with aggressive cancer phenotypes, tumor metastases, and poor patient outcomes in epithelial prostate and ovarian cancers 55, 56. This evidence concerns the gene SIRT7 and ovarian carcinoma.